secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001649094-24-000051
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Q2 net loss $128.7M; cash $1.85B; VAX-31 adult data due Sept 2024
-------------------------------------------------------------------------

- Net loss $128.7M for Q2 2024 vs $68.3M in Q2 2023; R&D expenses $131.5M, up from $72.7M.
- Cash, cash equivalents and investments $1,851.9M as of June 30, 2024, up from $1,242.9M at Dec 31, 2023.
- VAX-31 adult Phase 1/2 topline safety and immunogenicity data expected in September 2024; will then select VAX-24 or VAX-31 for Phase 3.
- VAX-24 infant Phase 2 topline from primary series due by end of Q1 2025; booster data by end of 2025.
- Appointed John Furey to Board; received $9.5M NIAID grant for Chlamydia vaccine program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909424000051/0001649094-24-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909424000051/pcvx-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001649094-24-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer